AREC — Arecor Therapeutics Income Statement
0.000.00%
- £28.33m
- £21.92m
- £4.57m
Annual income statement for Arecor Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 7 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.1 | 1.7 | 1.16 | 2.4 | 4.57 |
Cost of Revenue | |||||
Gross Profit | 1.1 | 1.7 | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2.67 | 5.13 | 7.6 | 13 | 13.7 |
Operating Profit | -1.57 | -3.43 | -6.44 | -10.6 | -9.18 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.57 | -3.51 | -6.95 | -10.5 | -8.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.28 | -2.75 | -6.17 | -9.26 | -8.55 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.28 | -2.75 | -6.17 | -9.26 | -8.55 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.28 | -2.75 | -6.17 | -9.26 | -8.55 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.046 | -0.099 | -0.255 | -0.316 | -0.279 |
Dividends per Share |